Novo Nomen Closes 11% of Global Staff Amid Competition from Obesity Drug Rivals—Bloomberg Hosts Live Q&A
Novo Nordisk is planning to reduce its global workforce by approximately 11% as part of a strategic effort to regain momentum in the competitive obesity-treatment market. The cut comes amid…